Company: DVAX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049536
Chunk: 214

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 214
---
, 2025 and December 31, 2024- - Common stock: $0.001 par value, 278,000 shares authorized at September 30, 2025 and December 31, 2024; 117,364 shares and 125,450 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively117 125 Additional paid-in capital1,486,947 1,504,671 Accumulated other comprehensive income800 (4,722)Accumulated deficit(953,726)(903,275)Total stockholders’ equity534,138 596,799 Total liabilities and stockholders’ equity$946,506 $986,256 

See accompanying notes.

4

Table of Contents

Dynavax Technologies Corporation 

Condensed Consolidated Statements of Operations 

(In thousands, except per share amounts) 

(Unaudited) 

Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Revenues:    Product revenue, net$89,954 $79,345 $246,785 $197,377 Other revenue4,922 1,285 11,697 7,837 Total revenues94,876 80,630 258,482 205,214 Operating expenses:    Cost of sales - product14,403 13,084 42,207 36,035 Research and development19,116 14,403 55,112 42,881 Selling, general and administrative40,086 43,061 138,123 128,788 Bad debt expense— — 10,970 — Total operating expenses73,605 70,548 246,412 207,704 Income (loss) from operations21,271 10,082 12,070 (2,490)Other income (expense):    Interest income6,593 9,382 21,130 28,050 Interest expense(1,643)(1,699)(4,976)(5,090)Sublease income2,225 2,205 6,677 2,808 Loss on debt extinguishment— — (82,095)— Other loss(27)(152)(1,046)(52)Net income (loss) before income taxes28,419 19,818 (48,